Genetic approach to diagnostic and therapeutic decisions in human hypertension

Current Opinion in Nephrology and Hypertension

Volumn 6, Issue 2, 1997, Pages 199-204

  Williams, Gordon H ^a   Fisher, Naomi D L ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENETICS; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW;

EID: 0030954279     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199703000-00015     Document Type: Review

References (64)

1. Ward R: Familial aggregation and genetic epidemiology of blood pressure. In Hypertension: Pathophysiology, Diagnosis and Management, vol 1, edn 2. New York: Raven Press Publishers; 1995:67-88.
2. Gelehrter TD, Collins FS: Principles of Medical Genetics, Williams & Wilkins: 1990, 57-65, 193-224.
3. Haseman JK, Elston RC: The investigation of linkage between a quantitative tait and a marker locus. Behav Genet 1972, 2:3-19.
4. Amos CI, Elston RC: Robust methods for the detection of genetic linkage for quantitative date from pedigrees. Genet Epidemiol 1989, 6:349-360.
5. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM: A chimeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 355:262-265.
6. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR Jr, Ulick S, Milora RV, Findling JW et al.: Liddle's syndrome: heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel. Cell 1994, 79:407-414.
7. Liddle GW, Bledsoe T, Coppage WS: A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians 1963, 76:199-213.
8. Schild L, Canessa CM, Shimlets RA, Gaitschi I, Lifton RP, Rossier BC: A mutation in the epithelial sodium channel causing Liddle's disease increases channel activity in Xenopus laevis oocyte expression system. Proc Natl Acad Sci U S A 1995, 92:56699-56703. The pathogenesis of Liddle's syndrome is explained by a constitutive increase in sodium channel activity.
9. Hansson JH, Nelson-Williams C, Suzuki H, Schild L, Shimkets R, Lu Y, Canessa C, Iwasaki T, Rossier B, Lifton R: Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle's syndrome. Nature Genet 1995, 11:76-80. A patient with Liddle's syndrome was shown to have a mutation in the γ subunit, not the β, demonstrating genetic heterogeneity of the syndrome.
10. Hansson JH, Schild L, Lu Y, Wilson TA, Gautschi I, Shimkets R, Nelson-Williams C, Rossier BC, Lifton RP: A de novo missense mutation of the beta subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity. Proc Natl Acad Sci U S A 1995, 92:11495-11499.
11. + channels by beta-subunit mutation. Am J Physiol 1996, 39:C208-C213.
12. + channels in Liddle's disease. Am J Physiol 1996, 39:C214-C223.
13. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS: Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type II enzyme. Mol Cell Endocrinol 1994, 105:11-17.
14. Mune T, Rogerson FM, Nikkila H, Agarwal AL, White PC: Human hypertension caused by mutations in the kidney isozyme of 11beta-hydroxysteroid dehydrogenase. Nature Genet 1995, 10:394-399. The gene encoding 11β-hydroxysteroid dehydrogenase was analyzed in 11 patients with the syndrome of apparent mineralocorticoid excess. Mutations causing marked decrease in enzymatic activity were found on both alleles in 9 patients.
15. Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghy-Azar M, Harbison MD, Wei JQ, Shackleton CHL, Funder JW, New MI: A mutation in HSD11beta2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1995, 80:2263-2266. With this first description of a mutation in the renal β-hydroxysteroid dehydrogenase isoenzyme in a family with apparent mineralocorticoid excess, two affected siblings in an Iranian family are shown to be homozygous for the mutation.
16. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM: Molecular basis of human hypertension: role of angiotensinogen. Cell 1992, 71:169-180.
17. Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P, Clark AJL: Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 1994, 330:1629-1633.
18. Caulfield M, Lavender P, Newell-Price J, Farrall M, Kamadar S, Daniel H, Lawson M, De Freitas P, Fogarty P, Clark AJL: Linkage of the AGT gene locus to human essential hypertension in African Caribbeans. J Clin Invest 1995, 96:687-692. Using the affected sibling pair approach, the range of populations in which the angiotensinogen locus has been linked to human essential hypertension is extended to Blacks of West African origin living in the Caribbean.
19. Tiret L, Ricard S, Poirier P, Arveiler D, Cambou JP, Luc G, Evans A, Nicaud V, Cambien F: Genetic variation at the angiotensinogen locus in relation to high blood pressure and mycoardial infarction: the ECTIM Study. J Hypertens 1995, 13:311-317. Within this study population of 630 European survivors of myocardial infarction, there was a 2.4-fold increase in the prevalence of hypertension in carriers of the abnormal angiotensinogen 174 allele, but only among lean patients.
20. Schmidt S, Sharma AM, Zilch O, Beige J, Walla-Friedel M, Ganten D, Distler A, Ritz E: Association of M235T variant of the angiotensinogen gene with familial hypertension of early onset. Nephrol Dial Transplant 1995, 10:1145-1148.
21. Fornage M, Turner ST, Sing CF, Boerwinkle E: Variation at the M235T locus of the angiotensinogen gene and essential hypertension: a population-based case-control study from Rochester, Minnesota. Hum Genet 1995, 96:295-300.
22. Rotimi C, Morrison L, Cooper R, Oyejide C, Effiong E, Lapids M, Osotemihen B, Ward R: Angiotensinogen gene in human hypertension: lack of an association of 235T allele among African-Americans. Hypertension 1994, 24:591-594.
23. Kamitani A, Rakugi H, Higaki J, Yi Z, Miki T, Ogihara T: Association analysis of a polymorphism of the angiotensinogen gene with essential hypertension in Japanese. J Hum Hypertens 1994, 8:521-524.
24. Ward K, Hata PF, Jeunemaitre X, Helin C, Nelson L, Namikawa C, Farrington PF, Ogasawara M, Suzumori K, Tomoda S et al.: A molecular variant of angiotensinogen associated with pre-eclampsia. Nature Genet 1993, 4:59-61.
25. Arngrimsson R, Purandare S, Connor M, Walker JJ, Bjornsson S, Soubrier F, Kotelevstev Y, Geirsson RT, Bjornsson H: Angiotensinogen: a candidate gene involved in preeclampsia. Nature Genet 1993, 4:114-115.
26. Rapp JP, Llang SM, Dene H: A genetic polymorphism in the renin gene of Dahl rats cosegregates with blood pressure. Science 1989, 243:542-544
27. Hilbert P, Lindpainter K, Beckmann JS, Serikawa T, Soubrier F, Dubay C, Cartwright P, De Gouyon B, Julier C, Takahashi S et al.: Chromosomal mapping of two genetic loci associated with blood pressure regulation in hereditary hypertensive rats. Nature 1991, 353:521-526.
28. Jacob JH, Lindpainter K, Lincoln SE, Kusumi K, Bunker RK, Mao YP, Ganten D, Dzau VJ, Lander ES: Genetic mapping of a gene causing hypertension in the stroke prone spontaneously hypertensive rat Cell 1991, 67:213-224
29. Naftilan AJ, Williams R, Burt D, Paul M, Pratt RE, Hobart P, Chirgwin J, Dzau VJ: A lack of linkage of renin gene restriction length polymorphisms with human hypertension. Hypertension 1989, 14:614-618.
30. Soubrier F, Jeunemaitre X, Rigat B, Houot AM, Cambien F, Corvol P: Similar frequencies of renin gene restriction fragment length polymorphisms in hypertensive and normotensive subjects. Hypertension 1990, 16:712-717.
31. Morris BJ, Griffith LR: Frequency in hypertensives of alleles for a RFLP associated with the renin gene. Biochem Biophys Res Commun 1988, 150:219-224.
32. Jeunemaitre X, Rigat B, Charru A, Houot AM, Soubrier F, Corvol P: Sib pair linkage analysis of renin gene haplotypes in human essential hypertension. Hum Genet 1992, 88:301-306.
33. Rigat B, Hubert C, Ahlenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990, 86:1343-1346.
34. Jeunemaitre X, Lifton RP, Hunt SC, Williams RR, Lalouel JM: Absence of linkage between the angiotensin converting enzyme and human essential hypertension. Nat Genet 1992, 1:72-75.
35. Ishigami T, Iwamoto T, Tamura K, Yamaguchi S, Iwasawa K, Uchino K, Umemura S, Ishii M: Angiotensin I converting enzyme (ACE) gene polymorphism and essential hypertension in Japan. Ethnic differences of ACE gentoype. Am J Hypertens 1995, 8:95-97.
36. Rutledge DR, Kubilis P, Browe CS, Ross EA: Polymorphism of the angiotensin I converting enzyme gene in essential hypertensive patients. Biochem Mol Biol Int 1995, 35:661-668.
37. Johnson AG, Simons LA, Friedlander Y, Simons J, Davis DR, Macallum J: I/D polymorphism of the angiotensin-converting enzyme gene does not predict isolated systolic or systolic diastolic hypertension in the elderly. J Hum Hypertens 1996, 10:171-176.
38. Maguchi M, Kohara K, Okura T, Li S, Takezaki M, Nishida W, Hiwada K: Angiotensin-converting enzyme gene polymorphism in essential hypertensive patients in Japanese population. Angiology 1996, 47:643-648.
39. Zee RYL, Lou YK, Griffiths LR, Morris BJ: Association of an insertion/ deletion polymorphism of the angiotensin I-converting enzyme gene with essential hypertension. Biochem Biophys Res Commun 1992, 184:9-15.
40. Barley J, Blackwood A, Miller M, Markandu ND, Carter ND, Jeffery S, Cappuccio FP, MacGregor GA, Sagnella GA: Angiotensin converting enzyme gene I/D polymorphism, blood pressure and the renin-angiotensin system in Caucasian and Afro-Caribbean peoples. J Hypertens 1996, 10:31-35.
41. Bloem LJ, Manatunga AK, Pratt JH: Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin I-converting enzyme activity. Hypertension 1996, 27:62-66.
42. Hiragi H, Oshima T, Watanabe M, Ishida M, Shingu T, Kambe M, Matsuura H, Kajiyama G: Angiotensin I-converting enzyme gene polymorphism and salt sensitivity in essential hypertension. Hypertension 1996, 27:569-572.
43. Marre M, Bernadet P, Gallois Y, Savagner F, Guyene TT, Hallab M, Cambien F, Passa P, Alhenc-Gelas F: Relationships between angiotensin I converting enzyme gene polymorphisms, plasma levels, and diabetic renal complications. Diabetes 1994, 43:384-388.
44. Schmidt S, Schone N, Ritz ED: Association of ACE gene polymorphism and diabetic nephropathy? The Diabetic Nephropathy Study Group. Kidney Int 1995, 47:1176-1181. In a large study designed to test the early association reported between the ACE gene polymorphism and the presence of nephropathy in Type I diabetes, no association between I/D polymorphisms and nephropathy was found either in type I or in type II diabetic individuals.
45. Ukkola O, Savolainen MJ, Salmela PI, von Dickhoff K, Kiema T, Kesaniemi YA: Insertion/deletion polymorphism in the angiotensin-converting enzyme gene associated with macroangiopathy and blood pressure in patients with non-insulin-dependent diabetes mellitus. J Mol Med 1995, 73:307-311.
46. Wierzbicki AS, Nimmoi L, Feher MD, Cox A, Foxton J, Lant AF: Association of angiotensin converting enzyme DD genotype with hypertension in diabetes. J Hum Hypertens 1995, 9:671-673.
47. Doria A, Onuma T, Gearin G, Freire MBS, Warram JH, Krolewski AS: Angiotensinogen polymorphism 235T, hypertension and nephropathy in insulin-dependent diabetes. Hypertension 1996, 27:1134-1139. In a study aimed to determine whether the angiotensinogen 235T allele might influence susceptibility to nephropathy in Type I diabetes, no contribution of the polymorphism to high blood pressure was identified.
48. Missouris CG, Barley J, Jeffery S, Carter ND, Singer DRJ, MacGregor GA: Genetic risk for renal artery stenosis: association with deletion polymorphism in angiotensin 1-converting enzyme gene. Kidney Int 1996, 49:534-537.
49. Iwai N, Ohmichi N, Hanai K, Nakamura Y, Kinoshita M: Human SA gene locus as a candidate locus for essential hypertension. Hypertension 1994, 23:375-380.
50. •].
51. •].
52. •] stand amidst several times more reported positive and negative associations between gene polymorphisms and hypertension. Absence of linkage, when rigorously performed, is a useful result.
53. Schalin-Jantti C, Nikula-Ijas P, Huang X, Lehto M, Knudsen P, Syvanne M, Lehtovirta MT, Tikkanen T, Tikkanen I, Groop LC: Polymorphisms of the glycogen synthase gene in hypertensive and normotensive subjects. Hypertension 1996, 27:67-71.
54. Delanghe J, Duprez D, de Buyzere M, Robbrecht D, Bergez B, Leroux-Roels G, Clement D: MN blood group, a genetic marker for essential arterial hypertension in young adults. Eur Heart J 1995, 16:1269-1276.
55. Stevens PA, Brown MJ: Genetic variability of the ET-1 and the ETA receptor genes in essential hypertension. J Cardiovasc Pharmacol 1995, 26(suppl 3):9-12.
56. Rutledge DR, Sun Y, Ross EA: Polymorphisms within the atrial natriuretic peptide gene in essential hypertension. J Hypertens 1995, 13:953-955.
57. Gu XX, Spaepen M, Raeymaekers P, Guo C, Fagard R, Amery A, Lijnen P, Cassiman JJ: Lack of association between HLA class II polymorphisms and essential hypertension in a Belgian population. J Hum Hypertens 1995, 9:553-555.
58. Shoback DM, Williams GH, Moore TJ, Dluhy RG, Podolsky S, Hollenberg NK: Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension. J Clin Invest 1983, 72:2115-2124.
59. Hollenberg NK, Moore TJ, Shoback DM, Redgrave J, Rabinowe S, Williams GH: Abnormal renal sodium handling in essential hypertension: relation to failure of renal and adrenal modulation of responses to angiotensin II. Am J Med 1986, 81:412-418.
60. Baretta-Piccoli C, Pusterla C, Stadler P, Weidmann P: Blunted aldosterone responsiveness to angiotensin II in subjects with predisposition to essential hypertension. J Hypertens 1988, 6:57-61.
61. Lifton RP, Hopkins PN, Williams RR, Hollenberg NK, Williams GH, Dluhy RG: Evidence for heritability of non-modulating essential hypertension. Hypertension 1989, 13:884-889.
62. Williams GH, Dluhy RG, Litton RP, Moore TJ, Gleason R, Williams R, Hunt SC, Hopkins PN, Hollenberg NK: Non-modulation as an intermediate phenotype in essential hypertension. Hypertension 1992, 20:788-796.
63. Hopkins PN, Lifton RP, Hollenberg NK, Jeunemaitre X, Hallouin MC, Skuppin J, Williams CS, Dluhy RD, Lalouel JM, Williams RR, Williams GH: Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity. J Hypertens 1996, 14:199-207. This study represents a bridge between genetics and physiology, where polymorphisms of the angiotensinogen gene were shown to predict blunting of the renal vascular response to angiotensin II, an intermediate phenotype which is part of the syndrome of nonmodulation. The association was demonstrated among 120 normotensive and hypertensive White individuals.
64. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JECK, Brown MJ: Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995, 13:1602-1609. This report documents an influence of angiotensinogen gene polymorphisms on the depressor response to ACE inhibition.